Transactions
21
Insider / Xilio Therapeutics, Inc.
Frankenfield Christopher James
Chief Financial Officer at Xilio Therapeutics, Inc.
- Company
- Xilio Therapeutics, Inc.
- Ticker
- XLO
- First filing on record
- November 25, 2025
- Latest trade on record
- January 2, 2026
- SEC filings
- EDGAR ↗
Frankenfield Christopher James, Chief Financial Officer at Xilio Therapeutics, Inc., has disclosed 21 transactions in XLO since November 25, 2025: 0 purchases (0 open-market buys) and 1 sale, worth about $4,522 at the reported prices. The latest was filed January 5, 2026, 4 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
1
Avg. disclosure lag
4.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Frankenfield Christopher James made no purchases and 1 sale worth $5K, plus 20 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Frankenfield Christopher James has traded 1 stock on record; the largest by dollars is XLO.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 10 | 2,441,961 | — |
| D | Sale back to the company | 8 | 848,172 | — |
| M | Option exercise or conversion | 2 | 38,750 | — |
| S | Open-market sale | 1 | 7,030 | $4,522 |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 3 | 0 | 1 · $4,522 |
| 2025 | 18 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| XLO | Option / conversion M | January 1, 2026 | January 5, 2026 | 4d | 19,375 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| XLO | Other A | December 31, 2025 | January 5, 2026 | 5d | 668,789 | — | — | late10b5-1 planderivative | Form 4 ↗ | |
| XLO | Sell S | January 2, 2026 | January 5, 2026 | 3d | 7,030 | $1 | $4,522 | 10b5-1 plan | Form 4 ↗ | |
| XLO | Option / conversion M | January 1, 2026 | January 5, 2026 | 4d | 19,375 | — | — | 10b5-1 plan | Form 4 ↗ | |
| XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 300,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 300,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 150,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 150,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 117,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 117,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 20,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 20,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 45,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 45,000 | — | — | derivative | Form 4 ↗ | |
| XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 37,296 | — | — | derivative | Form 4 ↗ | |
| XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 37,296 | — | — | derivative | Form 4 ↗ | |
| XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 23,786 | — | — | derivative | Form 4 ↗ | |
| XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 23,786 | — | — | derivative | Form 4 ↗ | |
| XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 155,090 | — | — | derivative | Form 4 ↗ | |
| XLO | Option / conversion D | November 21, 2025 | November 25, 2025 | 4d | 155,090 | — | — | derivative | Form 4 ↗ | |
| XLO | Other A | November 21, 2025 | November 25, 2025 | 4d | 925,000 | — | — | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| January 5, 2026 | Form 4 | 0001193125-26-002517 | 4 | published | EDGAR ↗ |
| November 25, 2025 | Form 4 | 0001193125-25-297204 | 17 | published | EDGAR ↗ |
Other insiders at Xilio Therapeutics, Inc.
- Russo Rene PRESIDENT AND CEO 20 rows
- Luptakova Katarina CHIEF MEDICAL OFFICER 14 rows
- Brennan Kevin M. SVP, FINANCE AND ACCOUNTING 11 rows
- Bonstein Sara Chief Financial Officer 10 rows
- GILEAD SCIENCES, INC. Insider 7 rows
- Shannon James Samuel Director 2 rows
- Bello Akintunde Olatokumbo Director 1 row
- Blanchard Cheryl R Director 1 row
- Brennan Aoife Director 1 row
- Curran Daniel J. Director 1 row
Everyone on file, with contracts and lobbying under the company's name: Xilio Therapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 21 | November 25, 2025 | January 5, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.